Table 2.
Ongoing trials of readily available vaccines for clinical trials against SARS-CoV-2
| Clinical trials for COVID-19 |
||||||
|---|---|---|---|---|---|---|
| Vaccine | Vaccination method | Identifier ID | Phase | Locations | Participants | Period |
| BCG | BCG vaccine Danish strain 1331 Concentrate and solvent for solution for intradermal injection | EudraCT 2020–000919-69 | Ongoing | Netherlands | 1000 | Ongoing from March, 2020 |
| BCG | multicentre, open label randomized controlled trial | NCT04327206 | Phase-III | Australia | 4170 | March to October, 2020 |
| BCG | randomized to vaccine: placebo in a 1:1 ratio | NCT04348370 | Phase-IV | Boston and Houston, USA | 1800 | April 20, 2020 to May 2021 |
| BCG | intradermal injection of BCG vaccine or placebo normal saline in a 2:1 ratio | NCT04350931 | Phase-III | Cairo, Egypt | 900 | April 20, 2020 to October, 2020 |
| BCG | randomized to vaccine and placebo using a 1: 1 allocation ratio | NCT04362124 | Phase-III | Medellín, Colombia | 1000 | April, 2020 to June, 2021 |
| BCG | randomized parallel study between two groups participants receiving vaccine or placebo | NCT04369794 | Phase-IV | Brazil | 1000 | June 2020 to June 2021 |
| BCG | randomized controlled trial of vaccine with placebo powder and solvent for dispersion for injection | EudraCT 2020–001678-31 | Ongoing | France | 1120 | Ongoing from April 17, 2020 |
| BCG | multi-center randomized placebo-controlled parallel study | NCT04373291 | Phase-III | Denmark | 1500 | May, 2020 to December 2020 |
| Measles-Mumps-Rubella (MMR) Vaccine | randomized parallel assignment | NCT04357028 | Phase-III | Cairo, Egypt | 200 | May 2020 to November, 2020 |